An all-comer targeting anticancer treatment Zejula is shooting yet again for the healthcare reimbursement expansion this year.

The pharmaceutical industry insider reported the drug could not overcome the hurdle of the Health Insurance Review and Assessment Service (HIRA) Cancer Deliberation Committee in last June, but the poly ADP-ribose polymerase (PPARP) inhibitor Zejula’s (niraparib), applied again in last August to expand the reimbursed indication. On Jan. 27, the Cancer Deliberation Committee would assess expanding the healthcare reimbursement on the drug’s indication as a monotherapy for the patients with platinum-sensitive relapsed high grade serous epithelial ovarian, fallopian tube, or prim